{
    "organizations": [],
    "uuid": "571fbb805f79f82db5f5c4f828c3c96d576bff7f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-xultophy-approved-in-canada-for-tr/brief-xultophy-approved-in-canada-for-treatment-of-adults-with-type-2-diabetes-idUSFWN1RV0WC",
    "ord_in_thread": 0,
    "title": "BRIEF-Xultophy Approved In Canada For Treatment Of Adults With Type 2 Diabetes",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - Novo Nordisk A/S:\n* XULTOPHY APPROVED IN CANADA FOR THE TREATMENT OF ADULTS WITH TYPE 2 DIABETES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-18T22:05:00.000+03:00",
    "crawled": "2018-04-18T22:21:10.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "novo",
        "nordisk",
        "xultophy",
        "approved",
        "canada",
        "treatment",
        "adult",
        "type",
        "diabetes",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}